Form 4: Quest Diagnostics Director Acquires Shares

Quest Diagnostics Director Robert B. Carter acquired 6 shares of common stock through a dividend reinvestment plan.

Summary

• Robert B. Carter, a Director at Quest Diagnostics Inc. (DGX), acquired 6 shares of common stock.
• The transaction occurred on October 21, 2025, at a price of $189.089 per share.
• The shares were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker.
• Following this transaction, Robert B. Carter beneficially owns a total of 2,698 shares of Quest Diagnostics common stock.
• The transaction was reported early on Form 4, though it was eligible for deferred reporting on Form 5 under Rule 16a-6.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even a small amount through a dividend reinvestment plan, generally indicates continued confidence in the company's value and future prospects, contributing to a moderately positive sentiment.

Positives

• A director's acquisition of shares, even a small amount, can signal confidence in the company's future prospects and valuation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive landscape within the diagnostics sector.

Stakeholder Impact

• Shareholders may view the director's share acquisition as a minor positive signal of management's alignment with shareholder interests and belief in the company's value.

Key Dates

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Director Share Acquisition, Dividend Reinvestment Plan, Robert B. Carter